2020
Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy
Patil PA, Zhang X. Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. Archives Of Pathology & Laboratory Medicine 2020, 145: 571-582. PMID: 32338534, DOI: 10.5858/arpa.2020-0070-ra.Peer-Reviewed Original ResearchConceptsHepatobiliary injuryCheckpoint inhibitorsCPI therapyActive colitisPathologic manifestationsCytotoxic T-lymphocyte-associated protein 4 inhibitorsT-lymphocyte-associated protein 4 inhibitorsImmune checkpoint inhibitor therapyDeath ligand 1 (PD-L1) inhibitorsAdverse effectsChronic active colitisAdministration of steroidsCheckpoint inhibitor therapyDeath receptor-1Immune checkpoint inhibitorsBile duct injuryChronic active gastritisLigand 1 inhibitorsNodular regenerative hyperplasiaSecondary sclerosing cholangitisDifferential diagnostic considerationsProtein 4 inhibitorsSeverity of injuryIschemic colitisPanlobular hepatitis
2014
Pathology of Alcoholic Liver Disease
Celli R, Zhang X. Pathology of Alcoholic Liver Disease. Journal Of Clinical And Translational Hepatology 2014, 2: 103-109. PMID: 26357621, PMCID: PMC4521259, DOI: 10.14218/jcth.2014.00010.Peer-Reviewed Original ResearchAlcoholic liver diseaseLiver diseaseAlcohol consumptionLiver-related deathAlcohol-attributable burdenImportant differential diagnosisSeverity of diseaseLiver biopsyPathologic featuresPathologic manifestationsDifferential diagnosisPopulation alcohol consumptionDiseaseGlobal healthClinical workBiopsyPatientsPathophysiologyCliniciansDiagnosisLiverPathologySeverity